DrugPatentWatch Database Preview
Email this page to a colleagueSee Plans and Pricing
« Back to Dashboard
Raltitrexed is an investigational drug.
There have been 37 clinical trials for Raltitrexed. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2015.
The most common disease conditions in clinical trials are Colorectal Neoplasms, Neoplasm Metastasis, and Carcinoma. The leading clinical trial sponsors are Fudan University, National Cancer Institute (NCI), and Jiangsu Cancer Institute & Hospital.
There are six hundred and four US patents protecting this investigational drug and eight international patents.
Recent Clinical Trials for Raltitrexed
|A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer||Jiangsu Cancer Institute & Hospital||Phase 2|
|Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma||National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College||Phase 2|
|Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma||Beijing Konruns Pharmaceutical Co., Ltd.||Phase 2|
Top disease conditions for Raltitrexed
Top clinical trial sponsors for Raltitrexed
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Raltitrexed||Start Trial||Heat shock protein 70 (hsp-70) receptor ligands||Duke University (Durham, NC)||Start Trial|
|Raltitrexed||Start Trial||Compounds and their methods of use||Agios Pharmaceuticals, Inc. (Cambridge, MA)||Start Trial|
|Raltitrexed||Start Trial||Selective proton coupled folate transporter and folate receptor, and GARFTase inhibitor compounds and methods of using the same||Duquesne University of the Holy Spirit (Pittsburgh, PA)||Start Trial|
|Raltitrexed||Start Trial||Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus||Seattle Genetics, Inc. (Bothell, WA)||Start Trial|
|Raltitrexed||Start Trial||Method of diagnosing and treating cancer using B-catenin splice variants||The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Raltitrexed||World Intellectual Property Organization (WIPO)||2015148714||2034-03-25||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|